|
|
Volumn 11, Issue 6, 2012, Pages 735-739
|
|
The global cell therapy industry continues to rise during the second and third quarters of 2012
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE;
LENALIDOMIDE;
REN 001;
UNCLASSIFIED DRUG;
AMYOTROPHIC LATERAL SCLEROSIS;
BLOOD BANK;
BRAIN ISCHEMIA;
CELL DIFFERENTIATION;
CELL THERAPY;
CEREBROVASCULAR ACCIDENT;
CHRONIC DISEASE;
CLINICAL TRIAL (TOPIC);
DENDRITIC CELL;
DISEASE COURSE;
DOUBLE BLIND PROCEDURE;
EPITHELIUM CELL;
FUNDING;
GLIOBLASTOMA;
GOOD MANUFACTURING PRACTICE;
GOVERNMENT REGULATION;
GRAFT VERSUS HOST REACTION;
HUMAN;
INDUSTRY;
LAW;
MARKET;
MESENCHYMAL STEM CELL;
MULTIPLE SCLEROSIS;
MYELOMA;
ORGANOGENESIS;
OSTEOARTHRITIS;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PIGMENT CELL;
PIGMENT EPITHELIUM;
PRIORITY JOURNAL;
PROSTATE CANCER;
REGENERATIVE MEDICINE;
REVIEW;
STEM CELL;
UNITED STATES;
WRINKLE;
|
|
EID: 84870889053
PISSN: 19345909
EISSN: 18759777
Source Type: Journal
DOI: 10.1016/j.stem.2012.11.013 Document Type: Note |
|
Times cited : (23)
|
|
References (9)
|
